Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apogee Therapeutics, Inc. (APGE) SEC filings page on Stock Titan aggregates the company’s U.S. Securities and Exchange Commission disclosures, providing insight into its status as a Nasdaq-listed, clinical-stage biotechnology issuer. These documents include current reports on Form 8-K, financial statements, equity offering details and other regulatory information that frame Apogee’s development and financing activities in inflammatory and immunology (I&I) therapeutics.
Apogee’s Forms 8-K illustrate how the company reports material events such as quarterly financial results, interim clinical data for programs like APG777 and APG333, and the terms of underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement. Selected 8-Ks also summarize outcomes of the annual meeting of stockholders, including director elections, auditor ratification and advisory votes on executive compensation frequency.
Through these filings, investors can review Apogee’s reported research and development and general and administrative expenses, net losses, cash and marketable securities balances, and the impact of capital raises on its operating runway. Offering-related filings describe underwriting agreements, option exercises by underwriters, pre-funded warrant terms and associated legal opinions, all of which help clarify the structure of Apogee’s capital formation.
On Stock Titan, users can access Apogee’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents such as earnings-related 8-Ks and registration statement updates. This includes highlighting where the company discusses clinical trial timelines, interim data disclosures, and other items relevant to its I&I pipeline. The filings page also surfaces exhibits like press releases and data presentations incorporated into 8-Ks, as well as cover page information confirming that Apogee’s common stock trades on The Nasdaq Global Market under the symbol APGE.
For those monitoring regulatory developments, capital structure changes or disclosure around programs such as APG777, APG279 and APG333, the SEC filings page offers an organized view of Apogee’s official communications with regulators and investors.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski received a new stock option grant. On January 2, 2026, he was awarded an option to purchase 83,690 shares of Apogee Therapeutics common stock at an exercise price of $75.78 per share. The option was reported as held directly by the officer.
The option will vest in 48 equal monthly installments over four years from the grant date, as long as he continues providing service to the company. The option expires on January 2, 2036, and represents a long-term equity incentive rather than an immediate share purchase.
Apogee Therapeutics’ chief financial officer Jane Henderson reported stock sales and a new stock option grant. On January 2, 2026, she sold 1,920 shares of common stock at a weighted average price of $74.13 and 4,080 shares at a weighted average price of $75.20, under a Rule 10b5-1 trading plan adopted on September 27, 2024. On January 6, 2026, she sold an additional 2,000 shares at $80.00, leaving her with 185,371 common shares held directly.
Separately, on January 2, 2026, she received a stock option to purchase 83,690 shares of common stock at an exercise price of $75.78 per share. This option vests in 48 equal monthly installments over four years from the grant date, subject to her continued service, and is scheduled to expire on January 2, 2036.
Apogee Therapeutics, Inc. reports positive interim Phase 1b data for its anti-IL-13 antibody zumilokibart (APG777) in adults with mild-to-moderate asthma. The double-blind, placebo-controlled study enrolled 31 patients randomized 3:1 to a single 720 mg dose of zumilokibart or placebo, and included a key analysis set of 19 patients with elevated FeNO, a biomarker of Type 2 inflammation. The company also noted observed improvements in asthma and sinusitis symptom scores in its APEX Phase 2 Part A atopic dermatitis trial and highlighted additional data readouts and milestones expected in 2026. Apogee stated it believes it has cash runway into the second half of 2028.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Henderson reported insider sales of common stock. On December 10, 2025, he sold a total of 20,000 shares of Apogee common stock in three transactions at weighted-average prices of $74.88, $75.79, and $76.58 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.
Following these sales, Henderson beneficially owns 1,212,987 shares of Apogee common stock directly. Some of the reported prices represent weighted averages for multiple trades executed within price ranges from $74.30 to $75.29 and from $75.30 to $76.28 per share, and he has agreed to provide detailed trade information to Apogee, any shareholder, or the SEC upon request.
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a sale of company stock. On December 4, 2025, he sold 10,900 shares of Apogee Therapeutics common stock at a weighted average price of about $75 per share, through multiple transactions between $75.00 and $75.01. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024. After these sales, he directly beneficially owns 271,108 shares of Apogee Therapeutics common stock.
Apogee Therapeutics, Inc. (APGE) reported an insider stock sale by its Chief Financial Officer, who is a reporting officer of the company. On 11/14/2025, the officer sold 2,000 shares of common stock at a price of $65 per share, in a transaction coded as an "S" sale. After this transaction, the officer beneficially owned 197,871 shares of Apogee common stock in direct ownership form. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was adopted on September 27, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
Apogee Therapeutics (APGE) reported an insider transaction by its Chief Financial Officer, Jane Pritchett Henderson. On 11/11/2025, she sold 1,000 shares of common stock at $60 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 27, 2024. Following the sale, she beneficially owns 199,871 shares, held directly.
Apogee Therapeutics (APGE) filed a Form 4 reporting insider sales by CEO and director Michael Henderson. On 11/13/2025, he sold a total of 20,000 shares in four transactions executed under a Rule 10b5-1 trading plan adopted on August 13, 2025.
Weighted average prices were $61.93 (range $61.45–$62.39), $63.14 (range $62.50–$63.47), $63.89 (range $63.52–$64.39), and $64.52. Following these sales, Henderson directly beneficially owns 1,272,987 shares.
Apogee Therapeutics (APGE) filed its Q3 2025 report, showing a net loss of $65.0 million, driven by operating expenses of $71.3 million. Research and development was $54.2 million and general and administrative was $17.1 million. Interest income contributed $6.3 million.
Liquidity remained strong with cash and cash equivalents of $107.9 million, marketable securities of $419.4 million, and long-term marketable securities of $61.6 million as of September 30, 2025. The company recorded stockholders’ equity of $586.3 million and an accumulated deficit of $492.4 million. Management states these resources will fund operations for at least the next 12 months. Capital actions included $19.4 million of net proceeds from the at-the-market program in Q3 and, subsequently, approximately $324.1 million of net proceeds from an October 2025 underwritten offering of common stock and pre-funded warrants. As of November 3, 2025, shares outstanding were 68,320,229, including 54,833,587 voting and 13,486,642 non-voting shares.
Apogee Therapeutics (APGE) furnished an 8‑K noting two updates. The company issued an earnings press release covering the quarter ended September 30, 2025, and separately announced positive interim Phase 1 results from a healthy volunteer trial of APG333.
The earnings release is furnished as Exhibit 99.1 and the clinical data release as Exhibit 99.2. Both exhibits are furnished, not filed, under the Exchange Act.